rhEPO Market in China 2016-2020

  • ID: 3769365
  • Report
  • Region: China
  • 65 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • 3S Bio
  • Biosidus
  • Dragon Pharma
  • Kehua Bio-Engineering
  • LG Life Sciences
  • Shandong Kexing
  • MORE
About the Recombinant Human Erythropoietin (rhEPO) Market in China

Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein responsible for producing erythrocytes in the body. In the fetal stage, this protein is produced in the liver; it is secreted by the kidneys in adulthood. During anemic conditions, the body produces an excess of EPO, maintaining the normal levels of red blood cells (RBC). When the endogenous production of EPO is disturbed because of diseases or the use of medications, the normal RBC levels can be maintained by an external supply of EPO-stimulating agents (ESAs). These agents are similar to the natural EPO in structure and function and are administered as injections. They can be produced by recombinant DNA technology and are used to treat anemia due to kidney diseases, cancer, HIV, injuries, or neural diseases.

The analysts forecast the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the recombinant human erythropoietin (rhEPO) market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on application of rhEPO:

- End-stage renal disease (ESRD)
- Cancer
- Human immunodeficiency virus (HIV)
- Wounds and neural disease

The report, Recombinant Human Erythropoietin (rhEPO) Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- 3S Bio
- Shanghai Chemo
- Chengdu Di’ao
- NCPC Genetech
- Kyowa Hakko Kirin
- Shandong Kexing

Other prominent vendors
- Ahua Pharmaceutical
- Biosidus
- Dragon Pharma
- Huaxin High Biotechnology
- Kehua Bio-Engineering
- LG Life Sciences
- Shenzhen Sai Bao Er Bio-Pharmaceutical
- Sihuan
- Shenyang Sunshine Pharmaceutical
- Uni-Bio Science Group
- Wanbang Biochemical Pharmaceuticals

Market drivers
- Increase in chronic kidney disease (CKD) and dialysis patient population

Market challenges
- Complex manufacturing process

Market trends
- Exploitation of novel therapeutic areas

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3S Bio
  • Biosidus
  • Dragon Pharma
  • Kehua Bio-Engineering
  • LG Life Sciences
  • Shandong Kexing
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Erythropoietin: An overview
  • Clinical uses of EPO
  • Abusive uses of EPO
  • Risks of EPO use
PART 06: Global erythropoietin market

PART 07: China: Country snapshot
  • Social and economic conditions
  • Healthcare reforms
  • Healthcare infrastructure
PART 08: Opportunities for pharmaceutical vendors in China
  • Major pharmaceutical vendors in China
  • Opportunities for global and local vendors
PART 09: Biopharmaceutical market in China
  • Biosimilar market in China
  • Market size and forecast
PART 10: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 11: Market segmentation by end-user
  • Hospitals
  • Retail pharmacies
PART 12: Market segmentation by application
  • ESRD
  • Cancer
  • HIV
  • Wounds and neural disease
PART 13: Drug pricing and reimbursement in China
  • Market-driven drug pricing strategy
  • Scrutinization of illegal pricing of drugs
PART 14: Pipeline portfolio
  • NuPIAO
  • Uni-EPO-Fc
  • PEG-EPO
PART 15: Market drivers
  • Increase in CKD and dialysis patient population
  • Growth in prevalence of cancer
  • Support for local manufacturers
PART 16: Impact of drivers

PART 17: Market challenges
  • Complex regulatory framework and approval process
  • Complex manufacturing process
  • Development of alternative therapies
PART 18: Impact of drivers and challenges

PART 19: Market trends
  • Penetration of rhEPO drugs in grade I and II hospitals
  • Exploitation of novel therapeutic areas
  • Initiation of R&D activities by local/domestic vendors
PART 20: Vendor landscape
  • Competitive scenario
  • Market analysis 2015
  • 3S Bio
  • Shanghai Chemo
  • Chengdu Di'ao
  • NCPC Genetech
  • Kyowa Hakko Kirin
  • Shandong Kexing
  • Other prominent vendors
PART 21: Appendix
  • List of abbreviations
PART 22: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Historical timeline of EPO development
Exhibit 03: Globally approved EPO biosimilars
Exhibit 04: China GDP 2010-2014 ($ trillions)
Exhibit 05: China: Healthcare expenditure 2009-2013 (% of GDP)
Exhibit 06: Healthcare reforms in China
Exhibit 07: China pharmaceutical market overview: SWOT analysis
Exhibit 08: New drug approval (NDA) review process in China
Exhibit 09: New drug approval process in China
Exhibit 10: Drug registration classification and requirements in China
Exhibit 11: Notable achievements in biopharmaceutical industry in china
Exhibit 12: Biopharmaceutical market in China 2015-2020 ($ billions)
Exhibit 13: rhEPO market in China in global biopharmaceutical market 2015
Exhibit 14: rhEPO market in China 2015-2020 ($ millions)
Exhibit 15: Five forces analysis
Exhibit 16: rhEPO market in China by distribution channels 2015
Exhibit 17: Share of domestic rhEPO drugs in hospitals in China 2015
Exhibit 18: Changes in the drug pricing system before and after 2015 reforms
Exhibit 19: Pipeline portfolio: rhEPO market in China
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: S Bio: YoY revenue comparison of EPIAO 2014-2015 ($ millions)
Exhibit 23: SBio: Key takeaways
Exhibit 24: Shanghai Fosun: YoY revenue and growth rate of blood system products 2013-2015 ($ millions)
Exhibit 25: Shanghai Chemo: Key takeaways
Exhibit 26: Chengdu Di'ao: Key takeaways
Exhibit 27: NCPC Genetech Biotechnology: Key takeaways
Exhibit 28: Kyowa Hakko Kirin: Key takeaways
Exhibit 29: Shandong Kexing: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3S Bio
  • Biosidus
  • Dragon Pharma
  • Kehua Bio-Engineering
  • LG Life Sciences
  • Shandong Kexing
  • MORE
New Report Released: - Recombinant Human Erythropoietin (rhEPO) Market in China 2016-2020

The author of the report recognizes the following companies as the key players in the recombinant human erythropoietin (rhEPO) market in China: 3S Bio, Shanghai Chemo, Chengdu Di’ao, NCPC Genetech, Kyowa Hakko Kirin, and Shandong Kexing.

Other Prominent Vendors in the market are: Ahua Pharmaceutical, Biosidus, Dragon Pharma, Huaxin High Biotechnology, Kehua Bio-Engineering, LG Life Sciences, Shenzhen Sai Bao Er Bio-Pharmaceutical, Sihuan, Shenyang Sunshine Pharmaceutical, Uni-Bio Science Group, and Wanbang Biochemical Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “A major trend which will boost market growth is the exploitation of novel therapeutic methods. The use of EPO has expanded to therapeutic areas other than for the treatment of anemia. For instance, recombinant EPO therapy is used to treat cardio-renal anemia syndrome. Use of EPO has shown an improvement in left and right ventricular systolic function in such patients with the reduction in cardiac remodeling, brain natriuretic peptide (BNP) levels, and hospitalization rate. Apart from this, with the discovery of EPO receptors in non-erythroid tissues, EPO has been investigated as a novel therapeutic agent in diseases and therapeutic conditions, including spinal cord injury, depression, diabetes, and as an immunomodulating agent.”

According to the report, a key growth driver is the increase in CKD and dialysis patient population. An increase in the anemic population is expected to boost the market growth as EPO drugs are used as a treatment option for anemia. Anemia can be caused due to a number of diseases such as kidney disease, cancer, and HIV. In individuals with CKD, anemia develops due to the dysfunction of the kidneys. In this condition, the levels of EPO are low, which results in the development of anemia. Also, deficiency of iron, vitamin B12, and folic acid, which are essential for forming hemoglobin by RBCs, can result in anemia. The condition is aggravated in individuals undergoing dialysis; 80% of the individuals on dialysis are on EPO therapy to treat anemia

Further, the report states that one challenge that could restrict market growth is the complex manufacturing process. Unlike small molecule drugs, biologics are prepared from living organisms. Hence, the production process involved is complicated and time-consuming.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- 3S Bio
- Shanghai Chemo
- Chengdu Di’ao
- NCPC Genetech
- Kyowa Hakko Kirin
- Shandong Kexing
- Ahua Pharmaceutical
- Biosidus
- Dragon Pharma
- Huaxin High Biotechnology
- Kehua Bio-Engineering
- LG Life Sciences
- Shenzhen Sai Bao Er Bio-Pharmaceutical
- Sihuan
- Shenyang Sunshine Pharmaceutical
- Uni-Bio Science Group
- Wanbang Biochemical Pharmaceuticals.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll